Do analysts recommend KPRX or ORGS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, ORGS or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 3.90 -$55.36M -$11.51 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is ORGS or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate MDCX or ORGS?

Medicus Pharma currently has a consensus price target of $9.00, indicating a potential upside of 5,669.23%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Medicus Pharma is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MDCX or ORGS more profitable?

Medicus Pharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -263.24% Orgenesis -3,827.81% N/A -130.18%

Do analysts rate ENSC or ORGS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ENSC or ORGS more profitable?

Ensysce Biosciences has a net margin of -280.53% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Ensysce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ensysce Biosciences -280.53% -2,550.30% -320.49% Orgenesis -3,827.81% N/A -130.18%

Orgenesis (ORGS) Competitors

$0.50 +0.43 (+649.63%)

As of 09:35 AM Eastern

Compare

ORGS vs. FNCH, KPRX, PHXM, MDCX, and ENSC

Should you buy Orgenesis stock or one of its competitors? Orgenesis's main competitors and comparable companies include Finch Therapeutics Group (FNCH), Kiora Pharmaceuticals (KPRX), PHAXIAM Therapeutics (PHXM), Medicus Pharma (MDCX), and Ensysce Biosciences (ENSC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Orgenesis compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Orgenesis has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Orgenesis	$662K	3.90	-$55.36M	-$11.51	N/A

Finch Therapeutics Group has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Orgenesis	-3,827.81%	N/A	-130.18%

Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market.

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Orgenesis	Neutral

Summary

Orgenesis beats Finch Therapeutics Group on 6 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kiora Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Orgenesis	-3,827.81%	N/A	-130.18%

Kiora Pharmaceuticals has higher revenue and earnings than Orgenesis. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.72	-$10.84M	-$2.51	N/A
Orgenesis	$662K	3.90	-$55.36M	-$11.51	N/A

Kiora Pharmaceuticals has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, meaning that its share price is 216% more volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Orgenesis. Kiora Pharmaceuticals' average media sentiment score of 1.82 beat Orgenesis' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Very Positive
Orgenesis	Neutral

Summary

Kiora Pharmaceuticals beats Orgenesis on 9 of the 14 factors compared between the two stocks.

How does Orgenesis compare to PHAXIAM Therapeutics?

Orgenesis (NASDAQ:ORGS) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Orgenesis has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

PHAXIAM Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.90	-$55.36M	-$11.51	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
PHAXIAM Therapeutics	Neutral

Summary

PHAXIAM Therapeutics beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Orgenesis compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Medicus Pharma had 7 more articles in the media than Orgenesis. MarketBeat recorded 7 mentions for Medicus Pharma and 0 mentions for Orgenesis. Medicus Pharma's average media sentiment score of 0.04 beat Orgenesis' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Medicus Pharma	Neutral
Orgenesis	Neutral

22.6% of Orgenesis shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

Medicus Pharma currently has a consensus price target of $9.00, indicating a potential upside of 5,669.23%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Medicus Pharma is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Medicus Pharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-263.24%
Orgenesis	-3,827.81%	N/A	-130.18%

Medicus Pharma has higher earnings, but lower revenue than Orgenesis. Medicus Pharma is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A
Orgenesis	$662K	3.90	-$55.36M	-$11.51	N/A

Summary

Medicus Pharma beats Orgenesis on 9 of the 15 factors compared between the two stocks.

How does Orgenesis compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 1.9% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Ensysce Biosciences had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Ensysce Biosciences and 0 mentions for Orgenesis. Ensysce Biosciences' average media sentiment score of 0.60 beat Orgenesis' score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Ensysce Biosciences	Positive
Orgenesis	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ensysce Biosciences has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

Ensysce Biosciences has a net margin of -280.53% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Orgenesis	-3,827.81%	N/A	-130.18%

Ensysce Biosciences has higher revenue and earnings than Orgenesis. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.58	-$10.18M	-$2.76	N/A
Orgenesis	$662K	3.90	-$55.36M	-$11.51	N/A

Summary

Ensysce Biosciences beats Orgenesis on 8 of the 14 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGS vs. The Competition

Export

Metric	Orgenesis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.58M	$12.47B	$7.24B	$13.12B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-0.04	792.30	274.66	25.73
Price / Sales	3.90	1,004.91	686.13	110.82
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	-0.08	10.61	10.45	6.32
Net Income	-$55.36M	$2.81B	$3.48B	$359.89M
7 Day Performance	-15.25%	-0.73%	-1.05%	-0.23%
1 Month Performance	-13.79%	-2.63%	-4.36%	-4.16%
1 Year Performance	N/A	2.92%	16.36%	6.00%

Orgenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGS Orgenesis	N/A	$0.50 +649.6%	N/A	-50.6%	$2.58M	$662K	N/A	150
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
KPRX Kiora Pharmaceuticals	0.8629 of 5 stars	$2.60 flat	N/A	+1.5%	$11.50M	$16.02M	N/A	10	High Trading Volume
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MDCX Medicus Pharma	2.51 of 5 stars	$0.16 +2.7%	$9.00 +5,661.8%	-93.8%	$9.61M	N/A	N/A	N/A	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orgenesis (ORGS) Competitors

ORGS vs. FNCH, KPRX, PHXM, MDCX, and ENSC

How does Orgenesis compare to Finch Therapeutics Group?

Summary

How does Orgenesis compare to Kiora Pharmaceuticals?

Summary

How does Orgenesis compare to PHAXIAM Therapeutics?

Summary

How does Orgenesis compare to Medicus Pharma?

Summary

How does Orgenesis compare to Ensysce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orgenesis (ORGS) Competitors

ORGS vs. FNCH, KPRX, PHXM, MDCX, and ENSC

How does Orgenesis compare to Finch Therapeutics Group?

Which has better valuation and earnings, FNCH or ORGS?

Is FNCH or ORGS more profitable?

Which has more risk & volatility, FNCH or ORGS?

Do insiders & institutionals have more ownership in FNCH or ORGS?

Does the media favor FNCH or ORGS?

Summary

How does Orgenesis compare to Kiora Pharmaceuticals?

Do analysts recommend KPRX or ORGS?

Is KPRX or ORGS more profitable?

Which has better valuation and earnings, KPRX or ORGS?

Which has more volatility & risk, KPRX or ORGS?

Do insiders and institutionals have more ownership in KPRX or ORGS?

Does the media favor KPRX or ORGS?

Summary

How does Orgenesis compare to PHAXIAM Therapeutics?

Which has more risk & volatility, ORGS or PHXM?

Is ORGS or PHXM more profitable?

Which has preferable earnings and valuation, ORGS or PHXM?

Do insiders & institutionals hold more shares of ORGS or PHXM?

Does the media prefer ORGS or PHXM?

Summary

How does Orgenesis compare to Medicus Pharma?

Does the media favor MDCX or ORGS?

Do insiders and institutionals have more ownership in MDCX or ORGS?

Which has more risk and volatility, MDCX or ORGS?

Do analysts rate MDCX or ORGS?

Is MDCX or ORGS more profitable?

Which has preferable valuation and earnings, MDCX or ORGS?

Summary

How does Orgenesis compare to Ensysce Biosciences?

Do institutionals & insiders have more ownership in ENSC or ORGS?

Does the media favor ENSC or ORGS?

Do analysts rate ENSC or ORGS?

Which has more volatility and risk, ENSC or ORGS?

Is ENSC or ORGS more profitable?

Which has stronger earnings & valuation, ENSC or ORGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools